Promising evidence regarding the effect of immunomodulatory strategies in the setting of ACS is currently emerging, as Canakinumab demonstrated a reduction in mortality and hospitalization for HF in patients with a personal history of myocardial infarction and elevated CRP [104]. This evidence concerns the gene CRP and myocardial infarction.